ArticleGastroenterology2023
Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention.
Article in Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06638866 (Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer), which is not on this map. Cited by 334 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer
Who cites it
334 citing papers in PubMed, 5 syntheses or guidelines pooled it, 415 citations in OpenAlex.
- Modern Approaches to Diagnosis and Evaluation of Survival Prognosis in Patients with Pancreatic Cancer.International journal of molecular sciences · 2026Pooled it
- The prognostic value of CLDN18.2 expression in pancreatic ductal adenocarcinoma: a systematic review and individual patient data meta-analysis.Virchows Archiv : an international journal of pathology · 2026Pooled it
- High IntratumoralInternational journal of molecular sciences · 2026Pooled it
- Pooled it
- Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer.Immunity, inflammation and disease · 2026Observational
- Article
- Clinicopathological differences and risk factors of early- versus late-onset pancreatic cancer: A systematic review and meta-analysis.iScience · 2026Article
- Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.Nature medicine · 2026Article
- Web-based dynamic nomogram for forecasting overall survival and cancer-specific survival among individuals with lymph node-negative pancreatic cancer: based upon the SEER database.Clinics (Sao Paulo, Brazil) · 2026Article
- Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.Journal of gastroenterology · 2026Article
- Recent developments in cancer immuno-interception strategies.Trends in molecular medicine · 2026Review
- PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.Signal transduction and targeted therapy · 2026Review
- Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990-2023: an analysis based on the Global Burden of Disease Study 2023.Journal of gastrointestinal oncology · 2026Article
- Progress and challenges in expanding access to clinical trials in pancreatic cancer.Communications medicine · 2026Review
- Article
- Emerging Issue - Fatty Pancreas in Pancreatic Cystic Neoplasms: Results of a Matched Case-Control Study.Digestive diseases and sciences · 2026Article
- Emerging Issue - Fatty Pancreas in Pancreatic Cystic Neoplasms: Results of a Matched Case-Control Study.Digestive diseases and sciences · 2026Article
- Article
- Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.Biomarker research · 2026Review
274 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Pancreatic cancer usually results in poor survival with limited options for treatment, as most affected individuals present with advanced disease. Early detection of preinvasive pancreatic neoplasia and identifying molecular therapeutic targets provide opportunities for extending survival. Although screening for pancreatic cancer is currently not recommended for the general population, emerging evidence indicates that pancreatic surveillance can improve outcomes for individuals in certain high-risk groups. Changes in the epidemiology of pancreatic cancer, experience from pancreatic surveillance, and discovery of novel biomarkers provide a roadmap for new strategies for pancreatic cancer risk assessment, early detection, and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.